Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KANDLELIT-013 adjuvant MK-1084 plus pembrolizumab/berahyaluronidase alfa in resected KRAS G12C-mutant NSCLC
jRCT2071260063Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2026
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing MK-1084 + MK-3475A with Placebo + MK-3475A (2 arms). Primary endpoint: Disease-free survival. Planned start Dec 2026; status: recruiting.
02
Drugs
calderasibberahyaluronidase alfa + pembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2071260063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260063.